Safety, PK/PD, and Clinical Activity of KT-413 in Adult Patients With Relapsed or Refractory B-cell NHL

Diffuse Large B Cell Lymphoma Clinical Trial

Official title:

A Phase 1, Multicenter, Open-Label, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, PK/PD, and Clinical Activity of Intravenously Administered KT-413 in Adult Patients With Relapsed or Refractory B-cell NHL

Clinical Trial Details — Status: Suspended

Administrative data

• NCT number: NCT05233033
• Other study ID #: KT413-DL-101
• Status: Suspended
• Phase: Phase 1
• Start date: June 13, 2022
• Est. completion date: May 2025

Study information

• Verified date: November 2023
• Source: Kymera Therapeutics, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This Phase 1a/1b study will evaluate the safety, tolerability and the pharmacokinetics/ pharmacodynamics (PK/ PD) of KT-413 in patients with R/R NHL. The Phase 1a stage of the study will explore escalating doses of single-agent KT-413. The Phase 1b stage will be split into 2 expansion cohorts to further characterize the safety, tolerability and the pharmacokinetics/ pharmacodynamics (PK/ PD) of KT-413 in MYD88 mutant and MYD88 wild-type R/R DLBCL.

Recruitment information / eligibility

• Status: Suspended
• Enrollment: 80
• Est. completion date: May 2025
• Est. primary completion date: April 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Phase 1a Only:

• Histologically confirmed diagnosis of B-cell NHL according to the 2016 World Health Organization (WHO) classification. Diffuse large B-cell lymphoma (DLBCL) includes: DLBCL not otherwise specified (NOS) with or without MYC and BCL2 and/or BCL6 rearrangements; Epstein-Barr virus (EBV) positive DLBCL, NOS; human herpesvirus 8 (HHV8) positive DLBCL, NOS; DLBCL associated with chronic inflammation; and Primary cutaneous DLBCL, leg type. Patients with indolent lymphoma are eligible if they meet criteria for systemic treatment.

• Clinicopathological diagnosis of Waldenström's Macroglobulinemia (WM) based on the consensus panel criteria from the Second International Workshop on WM

• Histologically/cytologically confirmed relapsed/refractory Primary Central Nervous System Lymphoma (PCNSL) by cerebrospinal fluid (CSF) or biopsy. PCNSL patients are considered eligible if the Investigator believes that there is no other reasonable treatment alternative.

• Note: Patients with HIV-associated PCNSL are not eligible.

• Note: Patients with secondary CNS metastases are eligible assuming they meet other study criteria. Patients with secondary CNS metastases include those who have synchronous systemic and CNS involvement or those who have been previously treated and relapsed with isolated CNS involvement.

• Phase 1b Only: Histologically confirmed diagnosis of DLBCL according to the 2016 WHO classification including: DLBCL not otherwise specified (NOS) with or without MYC and BCL2 and/or BCL6 rearrangements; Epstein-Barr virus (EBV) positive DLBCL, NOS; HHV8+ DLBCL, NOS; DLBCL associated with chronic inflammation; and Primary cutaneous DLBCL, leg type.

• Disease relapsed and/or refractory to at least 2 accepted standard systemic regimens for all indications except PCNSL. For PCNSL, patients must be relapsed and/or refractory to at least 1 prior regimen.

• Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 at Screening.

• Adequate organ and bone marrow function, in the absence of growth factors

• Patients of child-bearing potential must use adequate contraceptive measures to avoid pregnancy for the duration of the study as defined in the protocol

Exclusion Criteria:

• Infection with hepatitis B (HBV), hepatitis C (HCV), or active viral infection with human immunodeficiency virus (HIV).

• Radiation treatment within 4 weeks prior to first dose of study drug, unless the tumor site continues to increase in size after the patient has completed radiotherapy treatment.

• Major surgery requiring general anesthesia within 4 weeks prior to first dose of study drug, unless the tumor site continues to increase in size after the patient has completed radiotherapy treatment.

• Ongoing unstable cardiovascular function including history of myocardial infarction within 3 months of planned start of study drug.

• Patient has not recovered from any clinically significant AEs of previous treatments to pre-treatment baseline or Grade 1 prior to first dose of study drug.

Related Conditions & MeSH terms

• Diffuse Large B Cell Lymphoma
• DLBCL
• Lymphoma
• Lymphoma, Large B-Cell, Diffuse
• MYD88 Gene Mutation
• Non Hodgkin Lymphoma

Intervention

Drug:
• KT-413
KT-413 will be supplied as 10mg/mL concentration frozen solution to be administered intravenously per the protocol defined dose level.

Locations

Country	Name	City	State
United Kingdom	University College London Hospitals	London
United Kingdom	University Hospital Southampton NHS Foundation Trust	Southampton
United States	University of Virginia Comprehensive Cancer Center	Charlottesville	Virginia
United States	Henry Ford Health System	Detroit	Michigan
United States	MD Anderson Cancer Center	Houston	Texas
United States	Norton Cancer Institute	Louisville	Kentucky
United States	Memorial Sloan Kettering Cancer Center	New York	New York
United States	MedStar Georgetown University Hospital	Washington	District of Columbia

Sponsors (1)

Lead Sponsor	Collaborator
Kymera Therapeutics, Inc.

Countries where clinical trial is conducted

United States,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	KT-413 levels in peripheral blood mononuclear cells	Phase 1a/1b	Blood samples for PD analysis collected at multiple visits during cycle 1 and cycle 2 (each cycle is 21 days)
Primary	To establish the Maximum Tolerated Dose (MTD)	Phase 1a	Within first 3 weeks of treatment
Primary	Number of Participants with protocol specified Dose Limiting Toxicities (DLTs)	Phase 1a	Within first 3 weeks of treatment
Primary	Dose recommended for future studies	Phase 1a/1b	Within first 3 weeks of treatment
Primary	Clinical Laboratory Abnormalities	Incidence and severity of clinical laboratory abnormalities in serum chemistry, hematology, coagulation parameters, and urinalysis tests as assessed by CTCAE v5.0 (Phase 1a/1b)	Clinical laboratory abnormalities will be assessed from the time ICF signature through 30 days post dose or prior to start of a new anticancer therapy
Primary	Adverse Event Parameters	Incidence and severity of adverse events as assessed by CTCAE v5.0 (Phase 1a/1b)	Adverse Event Parameters will be assessed from the time ICF signature through 30 days post dose or prior to start of a new anticancer therapy
Primary	ECG Parameters	Changes in the ECG parameters, including heart rate and measures PR, QRS, QT, and QTc intervals as assessed by CTCAE v5.0 Phase 1a/1b	ECG Parameters will be assessed from the time ICF signature through 30 days post dose or prior to start of a new anticancer therapy
Secondary	Area under the plasma concentration versus time curve for KT-413 from time zero to last quantifiable time point (AUC0-t)	Phase 1a/1b	Blood samples for PK analysis collected at multiple visits during cycle 1 and cycle 2 (each cycle is 21 days)
Secondary	Maximum Plasma Concentration of KT-413 (Cmax)	Phase 1a/1b	Blood samples for PK analysis collected at multiple visits during cycle 1 and cycle 2 (each cycle is 21 days)
Secondary	Time of maximum plasma concentration of KT-413 (Tmax)	Phase 1a/1b	Blood samples for PK analysis collected at multiple visits during cycle 1 and cycle 2 (each cycle is 21 days)
Secondary	Half-life of KT-413 [if data permits (T1/2)]	Phase 1a/1b	Blood samples for PK analysis collected at multiple visits during cycle 1 and cycle 2 (each cycle is 21 days)
Secondary	Amount of KT-413 excreted in urine from time zero to last collected timepoint (Ae0-t)	Phase 1a/1b	Urine samples for PK analysis collected during the first cycle (21 day cycle)
Secondary	Evidence of clinical activity of KT-413 as determined by Objective Response Rate (ORR)	Phase 1a/1b	From date of baseline scan until the date of first documented progression or date of death from any cause, whichever came first, about 18 months
Secondary	Duration of Response (DOR) as assessed by the Investigator	Phase 1a/1b	From date of baseline scan until the date of first documented progression or date of death from any cause, whichever came first, about 18 months
Secondary	Progression-free survival (PFS) as assessed by the Investigator	Phase 1b	From time of entry on study through progression, up to 18 months
Secondary	Disease Control Rate (DCR) as assessed by the investigator	Phase 1b	From date of baseline scan until the date of first documented progression or date of death from any cause, whichever came first, about 18 months
Secondary	Overall Survival (OS) as assessed by the investigator	Phase 1b	From time of entry on study through death or date last known alive at end of follow-up, up to 18 months